VRAX (Virax Biolabs Group) Float Percentage Of Total Shares Outstanding: 97.43% (As of Jul. 07, 2026)


VRAX Virax Biolabs Group Ltd VRAX
37 GF Score
Price $3.09
GF Value $1.15
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Virax Biolabs Group Float Percentage Of Total Shares Outstanding?

Virax Biolabs Group VRAX -0.64% 37 Float Percentage Of Total Shares Outstanding is 97.43% as of Jul. 07, 2026. GuruFocus rates VRAX with a GF Score™ of 37/100 and a GF Value™ of $1.15 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Virax Biolabs Group's float shares is 0.78 Mil. Virax Biolabs Group's total shares outstanding is 0.80 Mil. Virax Biolabs Group's float percentage of total shares outstanding is 97.43%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Virax Biolabs Group's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Virax Biolabs Group's Institutional Ownership is 12.39%.

VRAX
37GF Score
Virax Biolabs Group Ltd VRAX
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Virax Biolabs Group Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Virax Biolabs Group's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.78/0.80
=97.43%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 97.43% mean?
Virax Biolabs Group (VRAX) has a Float Percentage Of Total Shares Outstanding of 97.43% as of Jul. 07, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Virax Biolabs Group and its competitors.
Is Virax Biolabs Group's Float Percentage Of Total Shares Outstanding too high?
Virax Biolabs Group's current Float Percentage Of Total Shares Outstanding is 97.43%. Overall, Virax Biolabs Group has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's Float Percentage Of Total Shares Outstanding compare to BBLG and PKTX?
Virax Biolabs Group's Float Percentage Of Total Shares Outstanding of 97.43% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Virax Biolabs Group and its competitors. Virax Biolabs Group's current Float Percentage Of Total Shares Outstanding is 97.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.15, compared to a current price of $3.09 — trading 168.7% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 97.43%. Virax Biolabs Group's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current Float Percentage Of Total Shares Outstanding is 97.43% as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virax Biolabs Group (VRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued. The current stock price of $3.09 is trading 168.7% above its estimated GF Value™ of $1.15. GuruFocus considers Virax Biolabs Group to be Significantly Overvalued.

Key valuation signals for VRAX:

  • Float Percentage Of Total Shares Outstanding: 97.43%
  • GF Value™: $1.15 vs. price of $3.09 (168.7% above fair value)
  • GF Score™: 37/100 with 2 warning signs

No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virax Biolabs Group Business Description

Address Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
37GF Score

Get the complete analysis for VRAX

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.09
Price
$1.15
GF Value